[{"id":"7e70ebdc-cdaa-4580-9eb1-432961d43354","acronym":"CAMBRIA-2","url":"https://clinicaltrials.gov/study/NCT05952557","created_at":"2023-07-20T14:08:53.643Z","updated_at":"2025-02-25T14:18:07.526Z","phase":"Phase 3","brief_title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","source_id_and_acronym":"NCT05952557 - CAMBRIA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 5500","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 03/04/2030","primary_completion_date":" 03/04/2030","study_txt":" Completion: 05/06/2037","study_completion_date":" 05/06/2037","last_update_posted":"2025-02-18"},{"id":"accc8beb-5a40-4334-a4ae-f00e0d7cc772","acronym":"ELEVATE","url":"https://clinicaltrials.gov/study/NCT05563220","created_at":"2022-10-03T15:56:32.608Z","updated_at":"2025-02-25T14:17:18.649Z","phase":"Phase 1/2","brief_title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT05563220 - ELEVATE","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER • PIK3CA • CDK4","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 01/24/2023","start_date":" 01/24/2023","primary_txt":" Primary completion: 12/27/2026","primary_completion_date":" 12/27/2026","study_txt":" Completion: 12/28/2028","study_completion_date":" 12/28/2028","last_update_posted":"2025-02-18"},{"id":"10294ca2-7f84-44ce-af11-76cdd03b1746","acronym":"SERENA-2","url":"https://clinicaltrials.gov/study/NCT04214288","created_at":"2021-01-18T20:31:16.451Z","updated_at":"2025-02-25T14:40:27.343Z","phase":"Phase 2","brief_title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04214288 - SERENA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • camizestrant (AZD9833)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 04/22/2020","start_date":" 04/22/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2025-02-14"},{"id":"89c18e67-5d9f-4f4c-836e-d176238b546e","acronym":"CAMBRIA-1","url":"https://clinicaltrials.gov/study/NCT05774951","created_at":"2023-03-20T20:03:21.727Z","updated_at":"2025-02-25T15:20:21.062Z","phase":"Phase 3","brief_title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","source_id_and_acronym":"NCT05774951 - CAMBRIA-1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 4300","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 04/20/2027","primary_completion_date":" 04/20/2027","study_txt":" Completion: 05/29/2036","study_completion_date":" 05/29/2036","last_update_posted":"2025-02-11"},{"id":"a22b0db3-f6b3-489e-b362-7e9a7131a6f7","acronym":"ELECTRA","url":"https://clinicaltrials.gov/study/NCT05386108","created_at":"2022-05-23T15:53:51.405Z","updated_at":"2025-02-25T15:27:22.960Z","phase":"Phase 1/2","brief_title":"Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer","source_id_and_acronym":"NCT05386108 - ELECTRA","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-11"},{"id":"996991a4-16ed-4414-90f1-2f630a1b4a1d","acronym":"lidERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04961996","created_at":"2021-07-14T14:53:31.141Z","updated_at":"2025-02-25T15:35:10.567Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","source_id_and_acronym":"NCT04961996 - lidERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 4200","initiation":"Initiation: 08/27/2021","start_date":" 08/27/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 11/21/2033","study_completion_date":" 11/21/2033","last_update_posted":"2025-02-10"},{"id":"96089508-6422-493f-82c5-12ed65ed1d61","acronym":"ELCIN","url":"https://clinicaltrials.gov/study/NCT05596409","created_at":"2022-10-27T15:58:31.639Z","updated_at":"2025-02-25T16:33:10.407Z","phase":"Phase 2","brief_title":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","source_id_and_acronym":"NCT05596409 - ELCIN","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-07"},{"id":"0d7fca80-0420-4ead-a6c7-20e34e32d1a2","acronym":"pionERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06065748","created_at":"2023-10-04T16:11:25.824Z","updated_at":"2025-02-25T16:47:04.424Z","phase":"Phase 3","brief_title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","source_id_and_acronym":"NCT06065748 - pionERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1050","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-05"},{"id":"432f1e5f-02a6-4552-b299-64f4b470c25a","acronym":"heredERA","url":"https://clinicaltrials.gov/study/NCT05296798","created_at":"2022-04-20T16:53:29.043Z","updated_at":"2025-02-25T12:28:43.790Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","source_id_and_acronym":"NCT05296798 - heredERA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • EGFR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • tamoxifen • Perjeta (pertuzumab) • giredestrant (RG6171) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 922","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-04"},{"id":"65c1ec6b-055f-4603-b88a-18648345da78","acronym":"EMPRESS","url":"https://clinicaltrials.gov/study/NCT05659563","created_at":"2022-12-21T15:59:16.652Z","updated_at":"2025-02-25T16:54:37.319Z","phase":"Phase 2","brief_title":"Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] \u0026 Ki67≥10%","source_id_and_acronym":"NCT05659563 - EMPRESS","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • giredestrant (RG6171) • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-04"},{"id":"298b3e73-8efc-4e73-b46a-0f8a07bcd548","acronym":"EMBER-3","url":"https://clinicaltrials.gov/study/NCT04975308","created_at":"2021-07-23T13:52:36.804Z","updated_at":"2025-02-25T16:16:28.798Z","phase":"Phase 3","brief_title":"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT04975308 - EMBER-3","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 866","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 06/24/2024","primary_completion_date":" 06/24/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-01-24"},{"id":"9269d88a-71af-4eec-a570-d307ba265a41","acronym":"","url":"https://clinicaltrials.gov/study/NCT05509790","created_at":"2022-08-22T13:04:12.367Z","updated_at":"2025-02-25T16:18:04.362Z","phase":"Phase 1","brief_title":"A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer","source_id_and_acronym":"NCT05509790","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inluriyo (imlunestrant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 10/09/2022","start_date":" 10/09/2022","primary_txt":" Primary completion: 02/18/2024","primary_completion_date":" 02/18/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-01-24"},{"id":"c86caf36-50f7-4e83-bb56-4d558b8c9be3","acronym":"EMBER","url":"https://clinicaltrials.gov/study/NCT04188548","created_at":"2021-01-18T20:25:02.359Z","updated_at":"2025-02-25T13:53:03.697Z","phase":"Phase 1","brief_title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","source_id_and_acronym":"NCT04188548 - EMBER","lead_sponsor":"Eli Lilly and Company","biomarkers":" ER","pipe":" | ","alterations":" HER-2 negative • EGFR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • Perjeta (pertuzumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 12/10/2019","start_date":" 12/10/2019","primary_txt":" Primary completion: 06/29/2020","primary_completion_date":" 06/29/2020","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-01-22"},{"id":"cbfdb786-2bdb-4bd6-ab84-5ea52effef85","acronym":"EMBER-4","url":"https://clinicaltrials.gov/study/NCT05514054","created_at":"2022-08-24T21:07:46.773Z","updated_at":"2025-02-25T16:18:06.124Z","phase":"Phase 3","brief_title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","source_id_and_acronym":"NCT05514054 - EMBER-4","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 03/01/2032","study_completion_date":" 03/01/2032","last_update_posted":"2025-01-22"},{"id":"61d86a30-55c7-41a4-bec4-37a547f93c03","acronym":"OP-1250-003","url":"https://clinicaltrials.gov/study/NCT05508906","created_at":"2022-08-19T17:10:19.756Z","updated_at":"2025-02-25T15:54:36.272Z","phase":"Phase 1","brief_title":"Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus","source_id_and_acronym":"NCT05508906 - OP-1250-003","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Piqray (alpelisib) • Kisqali (ribociclib) • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-10-03"},{"id":"469f79f5-7bed-470f-bde8-dd6a3a9d7203","acronym":"GO39932","url":"https://clinicaltrials.gov/study/NCT03332797","created_at":"2021-01-17T18:03:30.772Z","updated_at":"2024-07-02T16:34:37.744Z","phase":"Phase 1","brief_title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT03332797 - GO39932","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 181","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-06"},{"id":"9b710d7c-4f9a-4b68-bdf9-a2e98a847a66","acronym":"acelERA BC","url":"https://clinicaltrials.gov/study/NCT04576455","created_at":"2021-03-16T19:52:58.652Z","updated_at":"2024-07-02T16:34:37.881Z","phase":"Phase 2","brief_title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","source_id_and_acronym":"NCT04576455 - acelERA BC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 303","initiation":"Initiation: 11/27/2020","start_date":" 11/27/2020","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 06/27/2025","study_completion_date":" 06/27/2025","last_update_posted":"2024-06-06"},{"id":"1250c179-6562-4901-865f-17545e9bd303","acronym":"ML43171","url":"https://clinicaltrials.gov/study/NCT05306340","created_at":"2022-04-01T21:53:28.059Z","updated_at":"2024-07-02T16:34:58.786Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","source_id_and_acronym":"NCT05306340 - ML43171","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • fulvestrant • dexamethasone • exemestane • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-05"},{"id":"cce3783a-1b27-4829-a8df-f2ffd2039cf7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541433","created_at":"2021-01-18T21:43:43.429Z","updated_at":"2024-07-02T16:34:37.966Z","phase":"Phase 1","brief_title":"A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer","source_id_and_acronym":"NCT04541433","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e camizestrant (AZD9833)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 07/29/2022","primary_completion_date":" 07/29/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-05"},{"id":"ce41ba1f-4d4f-4c72-ae06-d61cb6cc53c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04546009","created_at":"2021-01-18T21:44:38.264Z","updated_at":"2024-07-02T16:34:58.754Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","source_id_and_acronym":"NCT04546009","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 992","initiation":"Initiation: 10/09/2020","start_date":" 10/09/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/18/2027","study_completion_date":" 03/18/2027","last_update_posted":"2024-06-05"},{"id":"8637b136-3de4-40fa-8293-aa26c472595a","acronym":"SERENA-6","url":"https://clinicaltrials.gov/study/NCT04964934","created_at":"2021-07-16T13:53:17.689Z","updated_at":"2024-07-02T16:34:59.080Z","phase":"Phase 3","brief_title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","source_id_and_acronym":"NCT04964934 - SERENA-6","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-06-04"},{"id":"7d23d816-d6f4-41e9-9cb9-d2526c0cc2b3","acronym":"OPERA-01","url":"https://clinicaltrials.gov/study/NCT06016738","created_at":"2023-08-30T14:08:41.909Z","updated_at":"2024-07-02T16:34:59.724Z","phase":"Phase 3","brief_title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT06016738 - OPERA-01","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • anastrozole • exemestane • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-05-31"},{"id":"d4742e3b-806e-4bab-ae68-fb132b73b498","acronym":"MiRaDoR","url":"https://clinicaltrials.gov/study/NCT05708235","created_at":"2023-02-01T15:00:03.847Z","updated_at":"2024-07-02T16:35:00.523Z","phase":"Phase 2","brief_title":"A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population","source_id_and_acronym":"NCT05708235 - MiRaDoR","lead_sponsor":"MedSIR","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HR positive • HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Itovebi (inavolisib) • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1260","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/30/2028","primary_completion_date":" 12/30/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2024-05-29"},{"id":"bcad0e5d-8e9a-4e78-8773-942d97532535","acronym":"FUCHSia","url":"https://clinicaltrials.gov/study/NCT03926936","created_at":"2021-01-18T19:20:57.374Z","updated_at":"2024-07-02T16:35:00.857Z","phase":"Phase 2","brief_title":"FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study","source_id_and_acronym":"NCT03926936 - FUCHSia","lead_sponsor":"Frederic Amant","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 12/27/2022","study_completion_date":" 12/27/2022","last_update_posted":"2024-05-27"}]